Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3304071 | 0.81 | PDE5A (0.34) | PDE5ACA12CA1CA2CA9 | |
| SCHEMBL3311643 | 0.80 | TDP1 (0.47) | CA14 | |
| SCHEMBL1950353 | 0.70 | HDAC6 (0.35) | CA12CA1CA14 | |
| SCHEMBL4758704 | 0.69 | HDAC6 (0.34) | CA14 | |
| SCHEMBL20381100 | 0.68 | TDP1 (0.54) | CA12CA1CA2CA9 | |
| SCHEMBL3310209 | 0.68 | TDP1 (0.47) | CA12CA1CA2CA9 | |
| SCHEMBL17369727 | 0.68 | ESR2 (0.37) | CA12CA1CA2CA9 | |
| SCHEMBL28329436 | 0.65 | EPHX1 (0.40) | CA12CA1CA14 | |
| SCHEMBL4048708 | 0.65 | CA12 (0.49) | CA12CA1CA2CA9 | |
| SCHEMBL9331694 | 0.65 | ADH1B (0.41) | PDE5ACA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266820-B2 | Nitric oxide donor compounds | NICOX SCIENCE IRELAND (IE) | 2016-02-23 | — | — | US | disclosed |
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
| US-20110052674-A1 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2250164-A2 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | Nicox S.A. (FR) | 2010-11-17 | — | — | EP | disclosed |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2010-04-22 | — | — | US | disclosed |
| EP-2125695-A2 | NITRIC OXIDE DONOR COMPOUNDS | Nicox S.A. (FR) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009106471-A2 | NEW ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | NICOX S.A. (FR) | 2009-09-03 | — | — | WO | disclosed |
| WO-2008095841-A2 | NITRIC OXIDE DONOR COMPOUNDS | NICOX S.A. (FR) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | PDE5A 72/4885CA12 4275/4885CA1 4365/4885 |
| US-20100099729-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | PDE5A 61/4885CA12 4290/4885CA1 4414/4885 |
| US-20110052674-A1 | ANGIOTENSIN II RECEPTOR BLOCKER DERIVATIVES | AGTR1, AGTR2, AGT | PDE5A 1571/4885CA12 4398/4885CA1 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.